摘要
糖尿病肾病是糖尿病最常见的微血管并发症之一,是导致终末期肾病的主要原因之一。糖尿病肾病发病机制复杂,治疗难度大,近年来钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂成为了治疗糖尿病肾病的研究热点,其可有效降低血糖,还可改善肾高滤过状态、改善肾缺氧、降低蛋白尿、减轻体重、降低血压、降低血尿酸、减轻炎症和氧化应激等。文章就SGLT-2抑制剂降糖特点、SGLT-2抑制剂对肾保护作用、SGLT-2抑制剂不良反应等三方面的研究进展作一综述。
Diabetic nephropathy(DN)is one of the most common microvascular complications of Diabetes mellitu.It is one of the leading causes of End-stage renal diseae(ESRD).The pathogenesis of DN is complex and difficult to treat.In recent years,Sodium-glucose cotransport 2(SGLT-2)inhibitors have become a research hotspot in the treatment of DN.They could effectively lower blood glucose,improve renal hyperfiltration and hypoxia,reduce urinary protein,weight,blood pressure and uric acid.In addition,SGLT2 is also anti-inflammatory and antioxidative,etc.This article reviews the progress of SGLT-2 inhibitors in 3 aspects,including the hypoglycemic characteristics,the protective effects of SGLT-2 inhibitors on the kidney,as well as the adverse reactions of SGLT-2 inhibitors.
作者
尹一帆(综述)
刘建(审校)
YIN Yi-fan;LIU Jian(Department of Nephrology,The Affiliated Hospital of Southwest Medical University,Nephropathy Clinical Medical Research Center of Sichuan Province,Luzhou 646000,Sichuan,China;Department of Nephrology,The Affiliated Chinese Traditional Medicine Hospital of Southwest Medical University,Luzhou 646000,Sichuan,China)
出处
《医学研究生学报》
CAS
北大核心
2020年第1期97-102,共6页
Journal of Medical Postgraduates
基金
四川省科学技术厅-泸州市人民政府-泸州医学院联合科研专项资金(LY-448)
关键词
钠-葡萄糖协同转运蛋白2
糖尿病肾病
肾保护
不良反应
sodium-glucose co-transport 2 inhibitors
diabetic nephropathy
kidney protection
adverse effects
